Apimeds Pharmaceuticals US APUS Growth Metrics (2024-2026)

NYSE APUS
$3.25 -0.25 (-7.14%)
As of: Oct 20, 2026 · 3:58 PM EDT
Reported Financials

Apimeds Pharmaceuticals US Quarterly Growth Metrics

Periods 8 quarters
Latest Jun 2026

Apimeds Pharmaceuticals US reported asset growth of 1,110.08% for the quarter ended Jun 2026. These growth metrics cover 8 quarters of results from Jun 2024 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

1Y3Y5Y7Y10YAll
Download Data
Growth MetricsGrowth Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Jun2026
Growth Ratios
Assets Growth (1y) -96.91%1,257,338.43%1,110.08%
Assets (QoQ) 1,890.53%3,957.91%-12.29%1,674.95%
Capital Expenditures (QoQ)Capex (QoQ) 76.52%
Cash & Equivalents Growth (1y)Cash & Equiv. Growth (1y) -99.16%47,270.62%-96.81%
Cash & Equivalents (QoQ)Cash & Equiv. (QoQ) 7,145.79%3,389.36%-20.02%-76.57%
Cash from Investing Activities (QoQ)Cash from Investing (QoQ) -44,374.01%
Cash from Operations Growth (1y)Cash from Ops. Growth (1y) 92.28%-1,726.14%-824.29%-3,732.92%
Cash from Operations (QoQ)Cash from Ops. (QoQ) 30.04%-1.47%46.66%79.61%-16,446.53%48.64%-121.20%
EBIT Growth (1y) -34.09%-522.76%-514.75%-2,454.32%-135.70%
EBIT (QoQ) -57.42%29.87%8.13%-32.20%-631.10%30.77%-281.73%
EBT Growth (1y) -35.73%-494.56%-439.55%-2,216.75%-254.86%
EBT (QoQ) -51.57%26.00%6.28%-29.13%-563.95%32.85%-302.41%
EPS (Basic) Growth (1y) -35.73%-351.58%-236.67%-169.27%-358.58%
EPS (Basic) (QoQ) -51.57%26.00%6.28%-29.13%-404.29%44.83%25.04%
EPS (Diluted) Growth (1y) -35.73%-351.58%-236.67%-169.27%-358.58%
EPS (Diluted) (QoQ) -51.57%26.00%6.28%-29.13%-404.29%44.83%25.04%
Free Cash Flow Growth (1y)FCF Growth (1y) 92.28%-1,726.14%-836.36%-3,772.86%
Free Cash Flow (QoQ)FCF (QoQ) 30.04%-1.47%46.66%79.61%-16,446.53%47.97%-120.62%
Interest Coverage Ratio Growth (1y)Interest Cover Growth (1y) 5.13%-497.61%-3,084.28%-327.06%98.31%
Interest Coverage Ratio (QoQ)Interest Cover (QoQ) -91.47%52.46%16.82%-25.31%-1,106.09%-153.30%88.84%
Net Cash Flow Growth (1y)NCF Growth (1y) 193.84%4,717.29%-4,657.74%-23,043.98%
Net Cash Flow (QoQ)NCF (QoQ) 30.04%80.03%37.11%1,168.04%3,342.20%-120.58%-205.94%
Net Income Growth (1y) -35.73%-492.44%-435.68%-270.72%-657.76%
Net Income (QoQ) -51.57%26.00%6.28%-29.13%-561.58%33.09%35.14%
Net Income towards Common Stockholders Growth (1y)Net Income Growth (1y) -35.73%-492.44%-435.68%-270.72%-657.76%
Net Income towards Common Stockholders (QoQ)Net Income (QoQ) -51.57%26.00%6.28%-29.13%-561.58%33.09%35.14%
Operating Income Growth (1y)Op. Inc Growth (1y) -34.09%-522.76%-514.75%-2,454.32%-135.70%
Operating Income (QoQ)Op. Inc (QoQ) -57.42%29.87%8.13%-32.20%-631.10%30.77%-281.73%
Profit After Tax Growth (1y)PAT Growth (1y) -35.73%-494.56%-439.55%-2,216.75%-254.86%
Profit After Tax (QoQ)PAT (QoQ) -51.57%26.00%6.28%-29.13%-563.95%32.85%-302.41%
Property, Plant & Equipment (Net) Growth (1y)PP&E (Net) Growth (1y) 295.29%
Property, Plant & Equipment (Net) (QoQ)PP&E (Net) (QoQ) 160.24%51.01%
Return on Assets [ROA] Growth (1y)ROA Growth (1y) 0.01M
Return on Assets [ROA] (QoQ)ROA (QoQ) 0.10M0.00M0.00M
Return on Capital Employed [ROCE] Growth (1y)ROCE Growth (1y) 0.01M
Return on Capital Employed [ROCE] (QoQ)ROCE (QoQ) 0.00M0.00M
Return on Equity [ROE] Growth (1y)ROE Growth (1y) 0.01M
Return on Equity [ROE] (QoQ)ROE (QoQ) 0.00M0.00M
Share-based Compensation (QoQ)Stock Comp. (QoQ) -77.78%4,140.19%
Total Debt Growth (1y) -6.33%2,736.51%
Total Debt (QoQ) 149.45%

Apimeds Pharmaceuticals US Growth Metrics API

Pull Apimeds Pharmaceuticals US's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key. 

https://data.businessquant.com/statements?ticker=APUS&statement=Growth&frequency=Quarter&period=all&api_key=YOUR_API_KEY
API documentation